Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease.

Sica, D A; Gehr, T W; Fernandez, A

Sica, D A; Gehr, T W; Fernandez, A.

Affiliation

Sica DA; Division of Clinical Pharmacology, Medical College of Virginia of Virginia Commonwealth University, Richmond 23298-0160, USA. dsica@hsc.vcu.edu

Drug Saf ; 22(5): 350-60, 2000 May.

Article in En | MEDLINE | ID: mdl-10830252

Subject(s)

Angiotensin-Converting Enzyme Inhibitors/adverse effects; Angiotensin-Converting Enzyme Inhibitors/therapeutic use; Angiotensins/antagonists & inhibitors; Antihypertensive Agents/adverse effects; Antihypertensive Agents/therapeutic use; Kidney Failure, Chronic/drug therapy; Angiotensin-Converting Enzyme Inhibitors/pharmacokinetics; Animals; Antihypertensive Agents/pharmacokinetics; Humans; Hypertension, Renal/drug therapy; Kidney Failure, Chronic/physiopathology; Risk Assessment

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Angiotensins / Angiotensin-Converting Enzyme Inhibitors / Kidney Failure, Chronic / Antihypertensive Agents Type of study: Etiology_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Drug Saf Journal subject: TERAPIA POR MEDICAMENTOS / TOXICOLOGIA Year: 2000 Document type: Article Affiliation country: United States Country of publication: New Zealand

Search on Google

Add to My VHL

XML

PubMed Links